Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Sep 20, 2018 7:00 AM - Sep 21, 2018 12:45 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

Advancing the Science of Study Endpoints


DIA’s Conference on clinical trial endpoints will bring together key stakeholders to address critical questions and generate potential solutions to challenges associated with determining study endpoints and outcomes. The 2018 Conference will examine global strategies for selecting study endpoints, and the impact of study endpoints during analysis of clinical evidence in the various types of drug approval processes. Hear from regulators, payers, patients, measurement experts, and others, as we navigate the complexities of developing and employing appropriate patient-focused endpoints for use in clinical trials. Discussions will cover the use of exit interviews, considerations for time to deterioration endpoints, and navigating the challenges of endpoints in small samples with heterogeneity, among other important topics that are critical across a broad set of stakeholders.

This program has been developed in collaboration with the Study Endpoints Community.

Want more on study endpoints? Check out two key sessions from the DIA 2018 Global Annual Meeting to get the latest on digital/mobile technology in clinical trials, and patient-focused outcomes. Download Sessions


Want to learn more about Advancing the Science of Study Endpoints? You've come to the right site!

Continuing Education

Who should attend?

Professionals involved in:

  • Industry
  • Academia
  • Government
  • Statistics
  • Clinical Trials
  • Health technology involved in
    • Setting, executing, or evaluating endpoint strategy for drug approval, labeling, promotion, translational science, and market access

Learning objectives

At the conclusion of this conference, participants should be able to:

  • Discuss the needs and requirements of critical stakeholders — patients, regulatory agencies, clinicians, payers — when identifying endpoints
  • Identify techniques for establishing the clinical relevance of changes in endpoints in clinical trials 
  • Explain the use of wearables for collecting study endpoint data in clinical trials

Program Committee

  • René  Allard, PhD
    René Allard, PhD Contractor
    CTC, Germany
  • Emuella  Flood
    Emuella Flood Director, Patient-Reported Outcomes
    AstraZeneca, United States
  • J. Jason  Lundy, PhD
    J. Jason Lundy, PhD Principal
    Outcometrix, United States
  • Matthew  Reaney, PhD, MSc
    Matthew Reaney, PhD, MSc Head of Science and Analytics, Patient Centered Solutions
    IQVIA, United Kingdom
  • Ashley F. Slagle, PhD, MS
    Ashley F. Slagle, PhD, MS Principal, Scientific and Regulatory Consulting
    Aspen Consulting, LLC, United States
  • Keith  Wenzel
    Keith Wenzel Volunteer
    DIA Study Endpoints Community, United States
  • Michael  Lees, MA
    Michael Lees, MA Chief Operating Officer and Head of Market Access Strategy
    PHMR Ltd, United Kingdom

Digital Learning Catalog

DIA Learning: eLearning Soultions

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.